Newer antihistaminic agents

Philip S. Norman

doi:10.1016/0091-6749(85)90655-4

Newer antihistaminic agents

Philip S. Norman

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Two new antihistamines with properties different from those of currently available drugs are nearing licensure. Named terfenidine and astemizole, they are almost exclusively H₁-antagonists, lacking anticholinergic and sympathetic activity. They fail to penetrate the central nervous system and lack sedative effects. They are long-acting and require less frequent doses. Thus they allow sustained antihistaminic action without the usual side effects.

Original language	English (US)
Pages (from-to)	366-368
Number of pages	3
Journal	The Journal of allergy and clinical immunology
Volume	76
Issue number	2 PART 2
DOIs	https://doi.org/10.1016/0091-6749(85)90655-4
State	Published - Aug 1985
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/0091-6749(85)90655-4

Cite this

@article{3491d0b0ae394677847f92c0c81e9002,

title = "Newer antihistaminic agents",

abstract = "Two new antihistamines with properties different from those of currently available drugs are nearing licensure. Named terfenidine and astemizole, they are almost exclusively H1-antagonists, lacking anticholinergic and sympathetic activity. They fail to penetrate the central nervous system and lack sedative effects. They are long-acting and require less frequent doses. Thus they allow sustained antihistaminic action without the usual side effects.",

author = "Norman, {Philip S.}",

year = "1985",

month = aug,

doi = "10.1016/0091-6749(85)90655-4",

language = "English (US)",

volume = "76",

pages = "366--368",

journal = "The Journal of allergy and clinical immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "2 PART 2",

}

TY - JOUR

T1 - Newer antihistaminic agents

AU - Norman, Philip S.

PY - 1985/8

Y1 - 1985/8

N2 - Two new antihistamines with properties different from those of currently available drugs are nearing licensure. Named terfenidine and astemizole, they are almost exclusively H1-antagonists, lacking anticholinergic and sympathetic activity. They fail to penetrate the central nervous system and lack sedative effects. They are long-acting and require less frequent doses. Thus they allow sustained antihistaminic action without the usual side effects.

AB - Two new antihistamines with properties different from those of currently available drugs are nearing licensure. Named terfenidine and astemizole, they are almost exclusively H1-antagonists, lacking anticholinergic and sympathetic activity. They fail to penetrate the central nervous system and lack sedative effects. They are long-acting and require less frequent doses. Thus they allow sustained antihistaminic action without the usual side effects.

UR - http://www.scopus.com/inward/record.url?scp=0022384599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022384599&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(85)90655-4

DO - 10.1016/0091-6749(85)90655-4

M3 - Article

C2 - 2862177

AN - SCOPUS:0022384599

SN - 0091-6749

VL - 76

SP - 366

EP - 368

JO - The Journal of allergy and clinical immunology

JF - The Journal of allergy and clinical immunology

IS - 2 PART 2

ER -

Newer antihistaminic agents

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this